NSE: ONESOURCE · 29 October 2026
- Onesource Specialty Pharma has risen 12.36% over 3 trading sessions; today's move is -0.48%.
- Onesource Specialty Pharma Limited reported its consolidated financial results for the quarter ended September 30, 2026, posting revenue of ₹5,162 million, up 37% year-on-year and 15% quarter-on-quarter. EBITDA reached ₹1,633 million, marking a 53% increase year-on-year with operating margins expanding to 31.6%, supported by new drug-device combination capacity and multi-segment product launches. Adjusted PAT stood at ₹937 million with an adjusted EPS of ₹8.2.
- Trading volume was 0.95 times the 20-day average daily volume.
Onesource Specialty Pharma share price: 12.36% rise over 3 trading sessions
Onesource Specialty Pharma Ltd. (ONESOURCE) traded down 0.48% at ₹1,570.0 on Wednesday, moving within a day's range of ₹1,564.0 to ₹1,596.2 after opening at ₹1,585.0.
The broader market and sector benchmarks recorded positive momentum during the session, with the Nifty advancing 1.05% and the Nifty Pharma sector index gaining 0.64%.
Company fundamentals remain supported by recent financial disclosures, including the company's Q2FY27 results announced on October 27, 2026, where revenue rose 37% year-on-year to ₹5,162 million and EBITDA grew 53% year-on-year to ₹1,633 million driven by new drug-device combination capacity. While this earnings report provides fundamental context for the broader business expansion, today's minor share price decline appears more aligned with short-term consolidation following recent strong appreciation rather than being directly triggered by fresh same-day news.
7.31 lakh shares traded by 29 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 7.73 lakh shares (0.95 times). The five-day average daily volume was 24.32 lakh shares. Separately, the NSE report for 28 October 2026 showed 10.44 lakh shares delivered, representing 27.40% of that day’s traded volume. The same report recorded 167,812 trades.
The stock experienced a minor pullback of 0.48% amidst positive broader market and sector trends, following a strong multi-day rally that yielded a 5-day return of 13.95%. No single same-day catalyst was identified, pointing to normal profit-taking and consolidation.
Latest Company Developments
Onesource Specialty Pharma Limited reported its consolidated financial results for the quarter ended September 30, 2026, posting revenue of ₹5,162 million, up 37% year-on-year and 15% quarter-on-quarter. EBITDA reached ₹1,633 million, marking a 53% increase year-on-year with operating margins expanding to 31.6%, supported by new drug-device combination capacity and multi-segment product launches. Adjusted PAT stood at ₹937 million with an adjusted EPS of ₹8.2.
Provides key financial metrics showing robust operational growth and capacity-driven scale across the specialty pharmaceutical CDMO business.
The Board of Directors approved the change in designation of Dr. Claudio Albrecht from Independent Director to Non-Executive Non-Independent Director, subject to shareholder approval. Dr. Albrecht brings extensive industry experience from leadership roles across international pharmaceutical and generics companies.
Reflects governance and board-level realignments as the company executes its ongoing strategic expansion.
a press release dated October 27, 2026, titled "OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY".
Onesource Specialty Pharma Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.
a press release dated October 27, 2026, titled "OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.76% on 30 September 2026. This compares with 12.98% on 30 June 2026, a change of +0.78 percentage points.
The filing reported 25 MF/UTI holders.
What to Watch Next
- Execution of commercial volume ramp-up for H2FY27 following new drug-device combination capacity additions
- Progress on additional international regulatory approvals and product launches in global markets
- Delivery trends and cash-market participation relative to the 20-day average volume
- Customer onboarding momentum in the biologics segment
Other Dated Coverage
- Onesource Specialty Pharma Share Price Today: Rises 12.90% in 2 Trading Sessions | 28 October 2026 — 28 October 2026
- Onesource Specialty Pharma Share Price Today: Rises 19.41% in 2 Trading Sessions | 27 October 2026 — 27 October 2026
More Onesource Specialty Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Onesource Specialty Pharma company news?
Onesource Specialty Pharma Limited reported its consolidated financial results for the quarter ended September 30, 2026, posting revenue of ₹5,162 million, up 37% year-on-year and 15% quarter-on-quarter. EBITDA reached ₹1,633 million, marking a 53% increase year-on-year with operating margins expanding to 31.6%, supported by new drug-device combination capacity and multi-segment product launches. Adjusted PAT stood at ₹937 million with an adjusted EPS of ₹8.2.
How strong was Onesource Specialty Pharma’s trading volume?
7.31 lakh shares traded, 0.95 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.